Management of hepatitis C virus in special populations: Patient and treatment considerations

被引:30
作者
Gish, RG
Afdhal, NH
Dieterich, DT
Reddy, KR
机构
[1] Calif Pacific Med Ctr, Liver Transplant Program, San Francisco, CA 94115 USA
[2] Calif Pacific Med Ctr, Div Hepatol & Complex GI, San Francisco, CA 94115 USA
[3] Beth Israel Deaconess Med Ctr, Ctr Liver, Boston, MA 02215 USA
[4] Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA
[5] Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA
关键词
D O I
10.1016/S1542-3565(04)00666-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The most common chronic blood-borne infection in the United States is caused by hepatitis C virus. An estimated 3.9 million people (1.8%) in the United States have been infected with the hepatitis C virus, excluding certain subpopulations who are at high risk for hepatitis C virus infection. Among these subpopulations are an estimated 255,000 (15%) of prison inmates and 175,000 (22%) of homeless people. Prevalence of hepatitis C virus infection is also high among veterans (6.6% overall and even higher among homeless veterans). The single most important risk factor for hepatitis C virus infection is injection drug use; up to 90% of illicit injection drug users are infected with hepatitis C virus. This review describes the prevalence of hepatitis C virus in special populations and discusses the treatment options for patients with severe disease, transplant recipients, and patients at high risk for infection. Close monitoring and management of therapeutic side effects are required to assist these patients in adhering to therapy.
引用
收藏
页码:311 / 318
页数:8
相关论文
共 68 条
[1]
Epoetin alfa treatment of anemic HCV-infected patients allows for maintenance of ribavirin dose, increases hemoglobin levels, and improves quality of life vs placebo: a randomized, double-blind, multicenter study [J].
Afdhal, NH ;
Dieterich, DT ;
Pockros, PJ ;
Schiff, ER ;
Shiffman, ML ;
Sulkowski, MS ;
Wright, T ;
Younossi, Z ;
Bowers, PJ .
GASTROENTEROLOGY, 2003, 124 (04) :A714-A714
[2]
Treatment of chronic hepatitis C in a state correctional facility [J].
Allen, SA ;
Spaulding, AC ;
Osei, AM ;
Taylor, LE ;
Cabral, AM ;
Rich, JD .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (03) :187-190
[3]
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].
Alter, MJ ;
Kruszon-Moran, D ;
Nainan, OV ;
McQuillan, GM ;
Gao, FX ;
Moyer, LA ;
Kaslow, RA ;
Margolis, HS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562
[4]
[Anonymous], 1998, MMWR Recomm Rep, V47, P1
[5]
[Anonymous], 2002, NIH Consens State Sci Statements, V19, P1
[6]
Treatment of hepatitis C infection in injection drug users [J].
Backmund, M ;
Meyer, K ;
Von Zielonka, M ;
Eichenlaub, D .
HEPATOLOGY, 2001, 34 (01) :188-193
[7]
Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation [J].
Berenguer, M ;
Prieto, M ;
Rayón, JM ;
Mora, J ;
Pastor, M ;
Ortiz, V ;
Carrasco, D ;
San Juan, F ;
Burgueño, MDJ ;
Mir, J ;
Berenguer, J .
HEPATOLOGY, 2000, 32 (04) :852-858
[8]
Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients [J].
Berenguer, M ;
Prieto, M ;
San Juan, F ;
Rayón, JM ;
Martinez, F ;
Carrasco, D ;
Moya, A ;
Orbis, F ;
Mir, J ;
Berenguer, J .
HEPATOLOGY, 2002, 36 (01) :202-210
[9]
BINI EJ, 2004, HLTH SERV RES DEV HS
[10]
Prevalence of hepatitis C and coinfection with HIV among United States Veterans in the New York City metropolitan area [J].
Bräu, N ;
Bini, EJ ;
Shahidi, A ;
Aytaman, A ;
Xiao, PY ;
Stancic, S ;
Eng, R ;
Brown, ST ;
Paronetto, F .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (08) :2071-2078